Skip to main content

Advertisement

Table 2 Shows the distribution of number of IVI, mean monthly ophthalmologic and total cost of the different treatment groups. Note that these are unadjusted values

From: Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context

Therapy # Eyes (patients) Mean # IVI (sda) Ophthalmologic costs per months [CHF] (sda) Total costs per months [CHF] (sda)
Only ranibizumab 182 (144) 4.3 (2.3) 1063.9 (549.3) 2060.5 (1274.4)
Only aflibercept 63 (52) 5.1 (2.5) 1238.8 (735.6) 2641.5 (1912.3)
Switching from ranibizumab to aflibercept prior study 160 (128) 5.9 (2.7) 1336.1 (742.2) 2486.8 (1702.0)
Switching from ranibizumab to aflibercept during study 45 (36) 6.9 (2.4) 1337.1 (443.1) 2408.5 (1133.6)
Miscellaneousb 38 (34) 6.6 (3.0) 1470.8 (770.5) 2404.5 (1141.9)
  1. asd = standard deviation
  2. bincluding eyes with various treatment regimens. The largest group consisted of 13 eyes with a double switch from ranibizumab to aflibercept and back to ranibizumab prior to study entry